Clinical trials: Metastatic Colorectal Cancer (MCRC)
Metastatic Colorectal Cancer (CRC)
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic…
- Trial name
- NCT06959693
- Testing
- Cetuxima-β, Envafolimab, mFOLFOX6
- Where
- China
- Volunteers
- 590 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
RAS Mutation, Metastatic Colorectal Cancer
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to…
- Conditions
- RAS Mutation, Metastatic Colorectal Cancer, MSS
- Trial name
- NCT06321081
- Testing
- irinotecan, cetuximab, envafolimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital
Metastatic Colorectal Cancer, Colorectal Neoplasms
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
Background: Gastrointestinal cancer is one of the most common cancers worldwide. Researchers think an unmet need exists to understand and improve treatment options.
- Conditions
- Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT04166383
- Testing
- Vascular Biogenics (VB)-111, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.
- Trial name
- NEXIRI (NCT00989469)
- Testing
- Nexavar (Sorafenib) and irinotecan (Campto)
- Where
- 5 sites in France
- Volunteers
- 64 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer
ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line
This is a national, multicentric, prospective, observational trial. The decision to prescribe FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab must have been freely taken by the clinician prior to the study…
- Trial name
- SILQ (NCT02624895)
- Where
- 31 sites in Italy
- Volunteers
- 296 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
- Trial name
- NCT01039506
- Testing
- CPT-11 based regimens
- Where
- Japan
- Volunteers
- 1,376 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
This phase I/II trial studies the side effects and how well encorafenib, binimetinib, and nivolumab work in treating patients with microsatellite stable, BRAFV600E gene-mutated colorectal cancer that has spread to other places in…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT04044430
- Testing
- Binimetinib, Encorafenib, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Metastatic Colorectal Cancer
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination…
- Trial name
- NCT04547166
- Testing
- HLX10, HLX04、
- Where
- 5 sites in China, Japan
- Volunteers
- 568 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer
A Phase Ib Study of Fruquintinib in 3rd Line mCRC
Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent…
- Trial name
- NCT01975077
- Testing
- fruquintinib
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Hutchison Medipharma Limited
Colorectal Cancer
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated…
- Trial name
- MAVERICC (NCT01374425)
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 376 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer (CRC), mCRC
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
This is a randomized, parallel, open-label, multicenter exploratory clinical study designed to investigate the efficacy and safety of iparomlimab and tuvonralimab in combination with fruquintinib plus heterogeneous radiotherapy…
- Trial name
- NCT07502014
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Fruquintinib, Heterogeneous Radiotherapy
- Volunteers
- 60 people
- Sponsor
- Huazhong University of Science and Technology
Metastatic Colorectal Cancer
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type…
- Trial name
- TAILOR (NCT01228734)
- Testing
- Cetuximab, Oxaliplatin, Folinic Acid
- Where
- 25 sites in China
- Volunteers
- 553 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer, mCRC
LifePearl-Iri Pharmacokinetic Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl microspheres loaded with irinotecan in the treatment of liver predominant mCRC by chemoembolization.
- Trial name
- NCT02547480
- Testing
- TACE with irinotecan loaded LifePearl
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Metastatic Colorectal Cancer (CRC)
Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)
This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC…
- Trial name
- RealCHALLENGE (NCT07536113)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Niguarda Hospital
Metastatic Colorectal Cancer
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients…
- Trial name
- NCT07025239
- Testing
- QL1706, Bevacizumab, Oxaliplatin
- Volunteers
- 430 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasm Metastasis, Colorectal Cancer
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor…
- Trial name
- OPUS (NCT00125034)
- Testing
- Cetuximab, Oxaliplatin
- Where
- 78 sites in Austria, Belgium and 11 more
- Volunteers
- 344 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Progression-Free Survival
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
- Trial name
- NCT06826092
- Testing
- Metformin Pill, FOLFIRI plus target therapy only
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metastatic Colorectal Cancer
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Compare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks
- Trial name
- NCT04835142
- Testing
- Double blind control period A140, Open single period A140
- Where
- China
- Volunteers
- 688 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.